Quinazoline derivatives for the treatment of cancer diseases
AssigneeBoehringer Ingelheim International GmbH
InventorsFlavio Solca, Andree Amelsberg, Jacobus C. A. van Meel, Anke Baum, Gerd Stehle
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of quinazolines of formula (I), wherein the groups Ra to Rd have the meanings given in the claims and specification, in cancer therapy.
Claims5
A method for treating metastatic non-small cell lung cancer (NSCLC) of squamous histology in a second line patient having failed at least one prior chemotherapy regimen, the method comprising administering to said patient a therapeutically effective amount of the compound 4-[(3-chloro-4-fluorophenyl)amino]-6-{[4-(N,N-dimethylamino)-1-oxo-2-buten-1-yl]amino}-7-((S)-tetrahydrofuran-3-yloxy)-quinazoline, or a physiologically acceptable salt thereof.
Dependencies are inferred from the claim text.